Hepatocyte nuclear factor-1beta - Revision history

Michael: +bladder

2025-01-02T21:07:22Z

+bladder

← Older revision		Revision as of 21:07, 2 January 2025
Line 13:		Line 13:
	*[[Prostate adenocarcinoma]].<ref name=pmid30065837/>		*[[Prostate adenocarcinoma]].<ref name=pmid30065837/>
	*Gastroesophageal adenocarcinoma.<ref name=pmid30065837/>		*Gastroesophageal adenocarcinoma.<ref name=pmid30065837/>
			*Bladder urothelial carcinoma ~40% positive.<ref>{{cite journal \|authors=Yang MX, Coates RF, Ambaye A, Gardner JA, Zubarick R, Gao Y, Skelly J, Liu JG, Mino-Kenudson M \|title=Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma \|journal=Biomark Res \|volume=6 \|issue= \|pages=25 \|date=2018 \|pmid=30065837 \|pmc=6062876 \|doi=10.1186/s40364-018-0139-6 \|url=}}</ref>

	==Negative==		==Negative==

Michael at 17:29, 5 August 2021

2021-08-05T17:29:37Z

← Older revision		Revision as of 17:29, 5 August 2021
Line 15:		Line 15:

	==Negative==		==Negative==
			*[[Serous carcinoma of the ovary]].
	*[[Hepatocellular carcinoma]].<ref name=pmid30065837/>		*[[Hepatocellular carcinoma]].<ref name=pmid30065837/>
	*[[Colorectal adenocarcinoma]].<ref name=pmid30065837/>		*[[Colorectal adenocarcinoma]].<ref name=pmid30065837/>
	*[[Breast adenocarcinoma]].<ref name=pmid30065837/>		*[[Breast adenocarcinoma]].<ref name=pmid30065837/>
	*[[Lung squamous cell carcinoma]].<ref name=pmid30065837/>		*[[Lung squamous cell carcinoma]].<ref name=pmid30065837/>

	~~==Negative==~~
	*[[Serous carcinoma of the ovary]].

	==References==		==References==

Michael: /* References */

2021-08-05T17:29:15Z

References

← Older revision		Revision as of 17:29, 5 August 2021
Line 24:		Line 24:

	==References==		==References==
	{{Reflist\|1}}		{{Reflist\|2}}

	[[Category:Immunohistochemistry]]		[[Category:Immunohistochemistry]]

Michael: /* Occasionally positive */

2021-08-05T17:29:01Z

Occasionally positive

← Older revision		Revision as of 17:29, 5 August 2021
Line 10:		Line 10:

	===Occasionally positive===		===Occasionally positive===
	*Lung adenocarcinoma.<ref name=pmid30065837/>		*[[Lung adenocarcinoma]].<ref name=pmid30065837/>
	*Prostate adenocarcinoma.<ref name=pmid30065837/>		*[[Prostate adenocarcinoma]].<ref name=pmid30065837/>
	*Gastroesophageal adenocarcinoma.<ref name=pmid30065837/>		*Gastroesophageal adenocarcinoma.<ref name=pmid30065837/>

Michael: /* Negative */

2021-08-05T17:28:34Z

Negative

← Older revision		Revision as of 17:28, 5 August 2021
Line 15:		Line 15:

	==Negative==		==Negative==
	*Hepatocellular carcinoma.<ref name=pmid30065837/>		*[[Hepatocellular carcinoma]].<ref name=pmid30065837/>
	*~~Colorecal~~ adenocarcinoma.<ref name=pmid30065837/>		*[[Colorectal adenocarcinoma]].<ref name=pmid30065837/>
	*Breast adenocarcinoma.<ref name=pmid30065837/>		*[[Breast adenocarcinoma]].<ref name=pmid30065837/>
	*Lung squamous cell ~~carcioma~~.<ref name=pmid30065837/>		*[[Lung squamous cell carcinoma]].<ref name=pmid30065837/>

	==Negative==		==Negative==

Michael: +more

2021-08-03T16:05:32Z

+more

← Older revision		Revision as of 16:05, 3 August 2021
Line 8:		Line 8:
	Note:		Note:
	*CA-125, RCCma, and CD10 can help distinguish ''clear cell renal cell carcinoma'' and ''Müllerian clear cell tumours''.<ref name=pmid25279712>{{cite journal \|authors=Mentrikoski MJ, Wendroth SM, Wick MR \|title=Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin \|journal=Appl Immunohistochem Mol Morphol \|volume=22 \|issue=9 \|pages=635–41 \|date=October 2014 \|pmid=25279712 \|doi=10.1097/PAI.0000000000000004 \|url=}}</ref>		*CA-125, RCCma, and CD10 can help distinguish ''clear cell renal cell carcinoma'' and ''Müllerian clear cell tumours''.<ref name=pmid25279712>{{cite journal \|authors=Mentrikoski MJ, Wendroth SM, Wick MR \|title=Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin \|journal=Appl Immunohistochem Mol Morphol \|volume=22 \|issue=9 \|pages=635–41 \|date=October 2014 \|pmid=25279712 \|doi=10.1097/PAI.0000000000000004 \|url=}}</ref>

			===Occasionally positive===
			*Lung adenocarcinoma.<ref name=pmid30065837/>
			*Prostate adenocarcinoma.<ref name=pmid30065837/>
			*Gastroesophageal adenocarcinoma.<ref name=pmid30065837/>

			==Negative==
			*Hepatocellular carcinoma.<ref name=pmid30065837/>
			*Colorecal adenocarcinoma.<ref name=pmid30065837/>
			*Breast adenocarcinoma.<ref name=pmid30065837/>
			*Lung squamous cell carcioma.<ref name=pmid30065837/>

	==Negative==		==Negative==

Michael: /* Positive */

2021-08-03T15:25:05Z

Positive

← Older revision		Revision as of 15:25, 3 August 2021
Line 4:		Line 4:
	*[[Clear cell carcinoma of the ovary]].		*[[Clear cell carcinoma of the ovary]].
	*[[Renal cell carcinoma]]s - including [[clear cell renal cell carcinoma]].<ref name=pmid26574638>{{cite journal \|authors=Hanley KZ, Cohen C, Osunkoya AO \|title=Hepatocyte Nuclear Factor-1β Expression in Clear Cell Renal Cell Carcinoma and Urothelial Carcinoma With Clear Cell Features: A Potential Diagnostic Pitfall \|journal=Appl. Immunohistochem. Mol. Morphol. \|volume=25 \|issue=2 \|pages=134–138 \|date=February 2017 \|pmid=26574638 \|doi=10.1097/PAI.0000000000000279 \|url=}}</ref><ref name=pmid32150988>{{cite journal \|authors=Kim M, Joo JW, Lee SJ, Cho YA, Park CK, Cho NH \|title=Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes \|journal=Cancers (Basel) \|volume=12 \|issue=3 \|pages= \|date=March 2020 \|pmid=32150988 \|pmc=7139472 \|doi=10.3390/cancers12030602 \|url=}}</ref>		*[[Renal cell carcinoma]]s - including [[clear cell renal cell carcinoma]].<ref name=pmid26574638>{{cite journal \|authors=Hanley KZ, Cohen C, Osunkoya AO \|title=Hepatocyte Nuclear Factor-1β Expression in Clear Cell Renal Cell Carcinoma and Urothelial Carcinoma With Clear Cell Features: A Potential Diagnostic Pitfall \|journal=Appl. Immunohistochem. Mol. Morphol. \|volume=25 \|issue=2 \|pages=134–138 \|date=February 2017 \|pmid=26574638 \|doi=10.1097/PAI.0000000000000279 \|url=}}</ref><ref name=pmid32150988>{{cite journal \|authors=Kim M, Joo JW, Lee SJ, Cho YA, Park CK, Cho NH \|title=Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes \|journal=Cancers (Basel) \|volume=12 \|issue=3 \|pages= \|date=March 2020 \|pmid=32150988 \|pmc=7139472 \|doi=10.3390/cancers12030602 \|url=}}</ref>
	*[[Pancreatic ductal adenocarcinoma]].<ref name=pmid30065837>{{cite journal \|~~vauthors~~=Yang MX, Coates RF, Ambaye A, Gardner JA, Zubarick R, Gao Y, Skelly J, Liu JG, Mino-Kenudson M \|title=Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma \|journal=Biomark Res \|volume=6 \|issue= \|pages=25 \|date=2018 \|pmid=30065837 \|pmc=6062876 \|doi=10.1186/s40364-018-0139-6 \|url=}}</ref>		*[[Pancreatic ductal adenocarcinoma]] and other [[foregut primary carcinomas]].<ref name=pmid30065837>{{cite journal \|authors=Yang MX, Coates RF, Ambaye A, Gardner JA, Zubarick R, Gao Y, Skelly J, Liu JG, Mino-Kenudson M \|title=Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma \|journal=Biomark Res \|volume=6 \|issue= \|pages=25 \|date=2018 \|pmid=30065837 \|pmc=6062876 \|doi=10.1186/s40364-018-0139-6 \|url=}}</ref>

	Note:		Note:

Michael: +PDAC

2021-08-03T15:23:33Z

+PDAC

← Older revision		Revision as of 15:23, 3 August 2021
Line 4:		Line 4:
	*[[Clear cell carcinoma of the ovary]].		*[[Clear cell carcinoma of the ovary]].
	*[[Renal cell carcinoma]]s - including [[clear cell renal cell carcinoma]].<ref name=pmid26574638>{{cite journal \|authors=Hanley KZ, Cohen C, Osunkoya AO \|title=Hepatocyte Nuclear Factor-1β Expression in Clear Cell Renal Cell Carcinoma and Urothelial Carcinoma With Clear Cell Features: A Potential Diagnostic Pitfall \|journal=Appl. Immunohistochem. Mol. Morphol. \|volume=25 \|issue=2 \|pages=134–138 \|date=February 2017 \|pmid=26574638 \|doi=10.1097/PAI.0000000000000279 \|url=}}</ref><ref name=pmid32150988>{{cite journal \|authors=Kim M, Joo JW, Lee SJ, Cho YA, Park CK, Cho NH \|title=Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes \|journal=Cancers (Basel) \|volume=12 \|issue=3 \|pages= \|date=March 2020 \|pmid=32150988 \|pmc=7139472 \|doi=10.3390/cancers12030602 \|url=}}</ref>		*[[Renal cell carcinoma]]s - including [[clear cell renal cell carcinoma]].<ref name=pmid26574638>{{cite journal \|authors=Hanley KZ, Cohen C, Osunkoya AO \|title=Hepatocyte Nuclear Factor-1β Expression in Clear Cell Renal Cell Carcinoma and Urothelial Carcinoma With Clear Cell Features: A Potential Diagnostic Pitfall \|journal=Appl. Immunohistochem. Mol. Morphol. \|volume=25 \|issue=2 \|pages=134–138 \|date=February 2017 \|pmid=26574638 \|doi=10.1097/PAI.0000000000000279 \|url=}}</ref><ref name=pmid32150988>{{cite journal \|authors=Kim M, Joo JW, Lee SJ, Cho YA, Park CK, Cho NH \|title=Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes \|journal=Cancers (Basel) \|volume=12 \|issue=3 \|pages= \|date=March 2020 \|pmid=32150988 \|pmc=7139472 \|doi=10.3390/cancers12030602 \|url=}}</ref>
			*[[Pancreatic ductal adenocarcinoma]].<ref name=pmid30065837>{{cite journal \|vauthors=Yang MX, Coates RF, Ambaye A, Gardner JA, Zubarick R, Gao Y, Skelly J, Liu JG, Mino-Kenudson M \|title=Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma \|journal=Biomark Res \|volume=6 \|issue= \|pages=25 \|date=2018 \|pmid=30065837 \|pmc=6062876 \|doi=10.1186/s40364-018-0139-6 \|url=}}</ref>

	Note:		Note:

Michael: /* Positive */ fix typo

2021-03-30T19:36:04Z

Positive: fix typo

← Older revision		Revision as of 19:36, 30 March 2021
Line 6:		Line 6:

	Note:		Note:
	*CA-125, RCCma, and CD10 can help distinguish ''clear cell renal cell carcinoma'' and ''Müllerian ~~cell~~ cell tumours''.<ref name=pmid25279712>{{cite journal \|authors=Mentrikoski MJ, Wendroth SM, Wick MR \|title=Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin \|journal=Appl Immunohistochem Mol Morphol \|volume=22 \|issue=9 \|pages=635–41 \|date=October 2014 \|pmid=25279712 \|doi=10.1097/PAI.0000000000000004 \|url=}}</ref>		*CA-125, RCCma, and CD10 can help distinguish ''clear cell renal cell carcinoma'' and ''Müllerian clear cell tumours''.<ref name=pmid25279712>{{cite journal \|authors=Mentrikoski MJ, Wendroth SM, Wick MR \|title=Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin \|journal=Appl Immunohistochem Mol Morphol \|volume=22 \|issue=9 \|pages=635–41 \|date=October 2014 \|pmid=25279712 \|doi=10.1097/PAI.0000000000000004 \|url=}}</ref>

	==Negative==		==Negative==

Michael: /* Positive */

2021-03-30T17:46:04Z

Positive

← Older revision		Revision as of 17:46, 30 March 2021
Line 3:		Line 3:
	==Positive==		==Positive==
	*[[Clear cell carcinoma of the ovary]].		*[[Clear cell carcinoma of the ovary]].
	*[[Renal cell carcinoma]] - including [[clear cell renal cell carcinoma]].<ref name=pmid26574638>{{cite journal \|authors=Hanley KZ, Cohen C, Osunkoya AO \|title=Hepatocyte Nuclear Factor-1β Expression in Clear Cell Renal Cell Carcinoma and Urothelial Carcinoma With Clear Cell Features: A Potential Diagnostic Pitfall \|journal=Appl. Immunohistochem. Mol. Morphol. \|volume=25 \|issue=2 \|pages=134–138 \|date=February 2017 \|pmid=26574638 \|doi=10.1097/PAI.0000000000000279 \|url=}}</ref><ref name=pmid32150988>{{cite journal \|authors=Kim M, Joo JW, Lee SJ, Cho YA, Park CK, Cho NH \|title=Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes \|journal=Cancers (Basel) \|volume=12 \|issue=3 \|pages= \|date=March 2020 \|pmid=32150988 \|pmc=7139472 \|doi=10.3390/cancers12030602 \|url=}}</ref>		*[[Renal cell carcinoma]]s - including [[clear cell renal cell carcinoma]].<ref name=pmid26574638>{{cite journal \|authors=Hanley KZ, Cohen C, Osunkoya AO \|title=Hepatocyte Nuclear Factor-1β Expression in Clear Cell Renal Cell Carcinoma and Urothelial Carcinoma With Clear Cell Features: A Potential Diagnostic Pitfall \|journal=Appl. Immunohistochem. Mol. Morphol. \|volume=25 \|issue=2 \|pages=134–138 \|date=February 2017 \|pmid=26574638 \|doi=10.1097/PAI.0000000000000279 \|url=}}</ref><ref name=pmid32150988>{{cite journal \|authors=Kim M, Joo JW, Lee SJ, Cho YA, Park CK, Cho NH \|title=Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes \|journal=Cancers (Basel) \|volume=12 \|issue=3 \|pages= \|date=March 2020 \|pmid=32150988 \|pmc=7139472 \|doi=10.3390/cancers12030602 \|url=}}</ref>

	Note:		Note: